4SZARO R C,SEXTON W T, MALONE C R. The emergence of ecosystem management as a tool for meeting people's needs and sustaining ecosystem[J]. Landscape and Urban Planning, 1998,40:1-7.
3Azamfirei L, Copotoiu SM, Branzaniuc K, et al.Complete blindness after optic neuropathy induced by short-term linezolid treatment in a patient suffering from muscle dystrophy[J].Pharmacoepidemiol Drug Saf, 2007, 16 (4) : 402.
4Rubinstein E, Isturiz R, Harold C, et al.Worldwide Assessment of Linezolid' s Clinical Safety and Tolerability: Comparator-Controlled Phase Ⅲ Studies[J]. Antimicrob Agents Chemother, 2003,47 (6) : 1 824.
5Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials [J].Lancet Infect Dis, 2008,8 ( 1 ) : 53.
6Bemstein WB, Trotta RF, Rector JT, et al.Mechanisms for linezolid-induced anemia and thrombocytopenia [J].Ann Pharmacother, 2003,37(4) : 517.
7SenneviUe E, Legout L, Valette M, et al.Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study[J]. J Antimicrob Chemother, 2004,54(4) : 98.
8Grau S, Morales-Molina JA, Mateu-de Antonio J.Linezolid: low pre-treatment platelet values could increase the risk of thrombocytopenia[J]. J Antimicrob Chemother, 2005,56(2) :440.
9Rao N, Ziran BH, Wagener MM, et al.Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections[J]. Clin Infect Dis, 2004,38 (8) : 1 058.
10Youssef S, Hachem R, Chemaly RF, et al.The role of vitamin B6 in the prevention of haematological toxic effects of linezolid in patients with cancer[J]. J Antimicrob Chemother, 2008,61 (2) : 421.
3Rice TW, Wheeler AP, Bemard GR, et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis[J]. Crit Care Med, 2010, 38 (8) : 1 685.
4Hayakawa M, Katabami K, Wada T, et al. Sivelestat (se- lective neutrophil elastase inhibitor) improves the mortali- ty rate of sepsis associated with both acute respiratory dis- tress syndrome and disseminated intravascular coagula- tion patients[J]. Shock, 2010,33( 1 ) : 14.
5Mokart D, Lambert J, Schnell D, et al. Delayed intensive care unit admission is associated with increased mortality in patients with cancer with acute respiratory failure[J]. LeukLymphoma, 2013,54(8) : 1 724.
6Salehifar E, Ala S, Amini M, et al. The role of clinical pharmacists in the improvement of a pharmacovigilance system: a review of the reported adverse drug reactions during 2004- 2010 in Mazandaran Province of Iran[J]. Journal fPharmaceutical Care, 2013,1 ( 1 ) : 8.
7Seoane L, Winterbottom F, Nash T, et al. Reaching impr- oved outcomes through the innovations of a multi- disci- plinary team: changing process of care for patients with severe sepsis and septic shock[J]. Critical Care Medicine, 2011,39( 12): 100.
8van Diepen S, Cook D J, Jacka M, et al. Critical care car- diology research:a call to action[J]. Circ Cardiovasc Qual Outcomes,2013,6(2) :237.
9Herasevich V, Pieper MS, Pulido J, et al. Enrollment into a time sensitive clinical study in the critical care setting: results from computerized septic shock sniffer implemen- tation[J]. J Am Med lnfirm Assoc, 201 1, 18 ( 5 ) : 639.
10Daley M J, Lat I, Mieure KD, et al. A comparison of ini- tial monotherapy with norepinephrine versus vasopressin for resuscitation in septic shock[J]. Ann Pharmacother, 2013,47(3) :301.
